Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Benzer Materyaller

• Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
  Yazar:: Okusaka, Takuji, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
  Yazar:: Suzuki, Eiichiro, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
  Yazar:: Ioka, Tatsuya, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
  Yazar:: Ikeda, Masafumi, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
  Yazar:: Ikeda, Masafumi, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)